After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...

As CDMOs across the industry continue to face pressure from a fluctuating biopharma business environment, AGC Biologics is ...

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices ...

Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three ...

Telix Pharmaceuticals tallied its third acquisition of the year with a deal worth up to $250 million for Florida-based RLS ...